Zelboraf: payments to doctors
Payments that named Zelboraf as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $76K
- Providers
- 21
- Transactions
- 42
- Average per transaction
- $1,801
The per-transaction average — $1,801 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 21 providers the average total is $3,601, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| F. Hoffmann-la Roche AG | $75,483 | 99.8% |
| Genentech USA, Inc. | $81 | 0.1% |
| Genentech, Inc. | $48 | 0.1% |
| Roche Products Limited | $14 | 0.0% |